About the ANCA-Associated Vasculitis Working Group

The methods for creating a composite outcome are different than for individual domain-directed outcomes and this Workshop will help attendees understand the steps required for this process through a project that is funded by ACR and EULAR to create response criteria for ANCA-associated vasculitis for use in clinical trials. Attendees are encouraged before the Workshop to view the short but highly informative videos developed to inform everyone on the disease under study and the methods employed for this project.

Haner_Direskeneli

Haner Direskeneli

Co-Chair

Peter Merkel

Peter Merkel

Co-Chair

gunnar

Gunnar Tómasson

Co-Chair

kaitlin quinn

Kaitlin Quinn

Fellow

Screen Shot 2021-02-17 at 11.40.13 AM

Sara Monti

Fellow

georgia lanier

Georgia Lanier

Patient Research Partner

Introduction to Antineutrophil cytoplasmic antibody ANCA-Associated Vasculitis

Introduction To Methodology To Develop A Composite Outcome Measure For ANCA-Associated Vasculitis

OMERACT Endorsed Core Set of Outcome Measures for Clinical Trials in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Screen Shot 2021-02-12 at 8.41.02 PM

Working Group Members:

Sibel Aydin
Maria Björk
Robin Christensen
Christian Dejaco
Haner Direskeneli
Peter Grayson
Gülen Hatemi
David Jayne
Tanaz Kermani
Carol Langford
Georgia Lanier

Sarah Mackie
Alfred Mahr
Alexa Meara
Peter Merkel
Nataliya Milman
Sara Monti
Christian Pagnoux
Kaitlin Quinn
Joanna Robson
Beverly Shea
Gunnar Tómasson

Scroll to Top